Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

120.00USD
29 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$120.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
197,518
52-wk High
$120.11
52-wk Low
$60.64

EW.N

Chart for EW.N

About

Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or... (more)

Overall

Beta: 0.58
Market Cap (Mil.): $12,724.01
Shares Outstanding (Mil.): 106.03
Dividend: --
Yield (%): --

Financials

Search Stocks

UPDATE 1-Edwards Lifesciences Q3 net rises 23 pct, outlook increased

Oct 23 - Medical device maker Edwards Lifesciences Corp on Thursday said its quarterly net earnings rose 23 percent on strong sales of heart valves, prompting the company to raise its full-year earnings outlook and sending its shares up 7 percent.

24 Oct 2014

Edwards 3rd quarter net rises 23 pct, 2014 outlook increased

Oct 23 - Medical device maker Edwards Lifesciences Corp on Thursday said its quarterly net earnings rose 23 percent due to strong sales of heart valves, prompting the company to raise its full-year earnings outlook.

24 Oct 2014

Allergan CEO resigns from Edwards Lifesciences' board

Oct 3 - Edwards Lifesciences Corp said David Pyott resigned from the medical device maker's board to devote more time to his role as chairman and CEO of Allergan Inc .

04 Oct 2014

UPDATE 2-Legal settlement lifts Edwards Lifesciences' profit

July 29 - Edwards Lifesciences Corp posted stronger second-quarter earnings on Tuesday, propelled by a gain from a legal settlement and higher sales of heart valves that are implanted using a less-invasive procedure than traditional open-heart surgery.

30 Jul 2014

Edwards Lifesciences posts higher profit

July 29 - Edwards Lifesciences Corp posted stronger second-quarter earnings on Tuesday, propelled by a gain from a legal settlement and higher sales of its heart valves that are implanted in a less-invasive procedure than traditional open-heart surgery.

30 Jul 2014

Edwards wins U.S. nod for next generation Sapien XT heart valve system

- Edwards Lifesciences Corp said on Monday that U.S. health regulators approved its next generation heart valve replacement system for high risk patients and those deemed too frail to endure open heart surgery.

17 Jun 2014

Edwards wins U.S. nod for next generation Sapien XT heart valve system

June 16 - Edwards Lifesciences Corp said on Monday that U.S. health regulators approved its next generation heart valve replacement system for high risk patients and those deemed too frail to endure open heart surgery.

17 Jun 2014

Medtronic settles heart valve patent fight with rival Edwards

- Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market.

20 May 2014

UPDATE 3-Medtronic settles heart valve patent fight with rival Edwards

May 20 - Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market.

20 May 2014

Medtronic settles heart valve patent dispute with Edwards

May 20 - Medtronic Inc on Tuesday said it has agreed to pay royalties to rival medical device maker Edwards Lifesciences Corp in a settlement agreement that allows Medtronic to continue to sell its CoreValve replacement heart valves.

20 May 2014

Earnings vs. Estimates

Search Stocks